Bottle Label 25 mg (71610 0177 09)
Jardiance Tablet, Film Coated
Product Images NDC 71610-177
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 71610-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
Empagliflozin Structure (Empagliflozin Structure)
Figure-1 (Figure 1)
Figure-2 (Figure 2)
Figure 3 (Figure 3)
The text provides a table showing the mean change from baseline HbA1c (%) over a 24-week period. The data compares a placebo group (N=185) to two groups treated with Empagliflozin (10mg and 25mg respectively) with N=206 and N=202. The data is adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*
Figure 4 (Figure 4)
The text describes the mean change from baseline HbA1c (%) values for two different treatments: Glimepiride + Metformin and Empaglifiozin 25 mg + Metformin. There are values shown for weeks 4, 12, 28, and 52. The values are adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*
Figure 5 (Jardiance Figure 5)
Figure 5 shows the cumulative incidence of first MACE (major adverse cardiovascular events) in patients treated with placebo and empagliflozin. The percentage of patients with events is shown on the left, while the subjects at risk are displayed on the bottom row. The chart includes two lines, one for placebo and one for empagliflozin. The x-axis represents time in months. Unfortunately, no further information is available in the given text.*
Figure 6 (Jardiance Figure 6)
This is a graph showing the estimated cumulative incidence of cardiovascular death in patients taking a placebo versus those taking Empagliflozin over a period of 48 months. It also shows the number of patients with an event as a percentage.*
Qr-code (Qr Code)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
